The factor V Leiden mutation in children with cancer and thrombosis
Maria T. Sifontes, Rachelle Nuss, Stephen P. Hunger et al. · British Journal of Haematology · 1997
Thromboembolic phenomena, frequently observed in children with cancer who are undergoing chemotherapy, can cause significant morbidity and, less frequently, mortality. Many contributory factors have been identified. Whether the recently identified and most common coagulation defect predisposing to thrombosis, factor V Leiden, is associated with thrombosis in this setting, has not been explored. The current study was undertaken to determine the prevalence of the factor V Leiden mutation in children with cancer who developed thromboembolic phenomena as compared to those with cancer who did not. Genomic DNA was amplified using the polymerase chain reaction (PCR), followed by digestion of the amplification product with the restriction enzyme MnlI. The digested PCR products were then size-fractionated to classify samples as heterozygous, homozygous or normal for the factor V Leiden mutation. 67 children with cancer were evaluated for the factor V Leiden mutation. One of 32 children with cancer and thrombosis, and none of 35 who had not experienced thrombotic problems, was found heterozygous for this mutation. We conclude that the factor V Leiden mutation does not play a significant role in the overall incidence of thromboses that occur in children with cancer.
Cited by 60 works. doi:10.1046/j.1365-2141.1997.d01-2046.x Open-access PDF
Authors
- Maria T. Sifontes
- Rachelle Nuss
- Stephen P. Hunger
- Judith A. Wilimas
- Linda J. Jacobson
- Marilyn J. Manco‐Johnson
References
- Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C.
- Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study
- Resistance to Activated Protein C as a Basis for Venous Thrombosis
- Mutation in the Gene Coding for Coagulation Factor V and the Risk of Myocardial Infarction, Stroke, and Venous Thrombosis in Apparently Healthy Men
- Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families
- Venous thromboembolic complications (VTE) in children: first analyses of the Canadian Registry of VTE
- Association of idiopathic venous thromboembolism with single point-mutation at Arg506 of factor V
- Inherited thrombophilia: resistance to activated protein C as a pathogenic factor of venous thromboembolism
- Activated protein C resistance caused by Arg506Gln mutation in factor Va
- Seminars in Thrombosis and Hemostasis